nivolumab + ipilimumab and chemotherapy, respectively. Grade 3e4 select TRAEs by category with nivolumab + ipilimumab included hepatic (8%), endocrine (4%), and skin (4%), and were consistent with previous reports. Median time to onset of select TRAEs ranged from 2 to 15 weeks, and the majority resolved (median time: 10 weeks). PRO results will be reported in the final presentation. Background: KEYNOTE-024 (NCT02142738) is a multicenter, international, phase 3, randomized, open-label trial of first-line pembrolizumab vs platinum-based chemotherapy for patients with advanced nonesmall-cell lung cancer (NSCLC; any histology) with PD-L1 tumor proportion score (TPS) 50% and without EGFR/ALK alterations. The primary analysis of KEYNOTE-024 showed significantly improved PFS (HR¼0.50; P<0.001) and OS (HR¼0.60; P¼0.005) with fewer treatment-related AEs with pembrolizumab compared with chemotherapy after a median follow-up of 11.2 months. We report on updated results after a median follow-up of 25.2 months. Method: Patients were randomized to pembrolizumab 200 mg every 3 weeks (35 cycles) or 4e6 cycles of investigator's choice of carboplatin/ cisplatin + gemcitabine, carboplatin + paclitaxel, or carboplatin/ cisplatin + pemetrexed with optional pemetrexed maintenance (for nonsquamous histology). Randomization was stratified by ECOG PS (0 vs 1), histology (squamous vs nonsquamous), and geographic region (East Asia vs noneEast Asia). Treatment continued until disease progression per RECIST version 1.1, intolerable toxicity, or withdrawal of consent. Patients in the chemotherapy arm could cross over to receive pembrolizumab monotherapy upon disease progression. Response was assessed every 9 weeks per RECIST version 1.1 by blinded independent central review (stopped after the second interim analysis) and by investigator assessment. PFS was the primary endpoint; OS and safety were secondary endpoints. Results: 305 patients were enrolled (pembrolizumab, n¼154; chemotherapy, n¼151). At data cutoff (July 10, 2017), 73 patients (47.4%) randomized to pembrolizumab and 96 patients (63.6%) randomized to chemotherapy had died. The hazard ratio (HR) for OS was 0.63 (95% confidence interval [CI], 0.47e0.86; nominal P¼0.002). Median (95% CI) OS was 30.0 (18.3enot reached) 
Background: KEYNOTE-024 (NCT02142738) is a multicenter, international, phase 3, randomized, open-label trial of first-line pembrolizumab vs platinum-based chemotherapy for patients with advanced nonesmall-cell lung cancer (NSCLC; any histology) with PD-L1 tumor proportion score (TPS) 50% and without EGFR/ALK alterations. The primary analysis of KEYNOTE-024 showed significantly improved PFS (HR¼0.50; P<0.001) and OS (HR¼0.60; P¼0.005) with fewer treatment-related AEs with pembrolizumab compared with chemotherapy after a median follow-up of 11.2 months. We report on updated results after a median follow-up of 25.2 months. Method: Patients were randomized to pembrolizumab 200 mg every 3 weeks (35 cycles) or 4e6 cycles of investigator's choice of carboplatin/ cisplatin + gemcitabine, carboplatin + paclitaxel, or carboplatin/ cisplatin + pemetrexed with optional pemetrexed maintenance (for nonsquamous histology). Randomization was stratified by ECOG PS (0 vs 1), histology (squamous vs nonsquamous), and geographic region (East Asia vs noneEast Asia). Treatment continued until disease progression per RECIST version 1.1, intolerable toxicity, or withdrawal of consent. Patients in the chemotherapy arm could cross over to receive pembrolizumab monotherapy upon disease progression. Response was assessed every 9 weeks per RECIST version 1.1 by blinded independent central review (stopped after the second interim analysis) and by investigator assessment. PFS was the primary endpoint; OS and safety were secondary endpoints. Results: 305 patients were enrolled (pembrolizumab, n¼154; chemotherapy, n¼151) . At data cutoff (July 10, 2017) Hispanics in the US have a lower age-adjusted mortality in NSCLC and have a different gene expression profile than NHW with higher prevalence of EGFR mutations then it's important to know if H can have similar outcomes to the ones described for NHW. Results: The median age was 65 years (range: 37-88y); most of the pts were males: 116 (54%), 82% adenocarcinomas. The ORR was 16% and the DCR that shows the clinical benefit was 67%. ORR and DCR were similar in adenocarcinomas (20%/68%) and squamous cell carcinomas (17%/64%) respectively. PFS at 6 months (m) and 12m were 80% and 56% respectively. Median PFS 14.5m and median OS were 19m, respectively. When patients were analyzed by PD-L1 status the ORR was 24% if PD-L1 (+) vs 1% if PD-L1 (-). STK11 was only tested in 13 pts, from the 7/11 (+) patients 60% achieved SD vs and the 2/2 pts that were (-) had PR. Conclusion: Hispanics might not have a benefit from immunotherapy to the extent that NHWs do, ORR for NSCLC pts treated with immunotherapy is 16% in Hispanics treated at 4 cancer centers compared to an expected 20% ORR for NHW as reported in the literature. We need a larger cohort and prospective studies to validate these findings in all genes. Keywords: Disparities, NSCLC, Hispanics, immunotherapy
PS5 New Biomarkers to Follow Therapy Response in Plasma of NSCLC Patients
Background: Immunotherapy (IMMUNO) has been successful in non-small cell lung cancer (NSCLC), however biomarkers are still in development. PD-L1 done by IHC in tissue has been the first one but blood based biomarkers present new opportunities. Circulating cell-free tumor RNA (cfRNA) can be now isolated and used to measure changes in the tumor burden and genome. We are correlating these changes in cfRNA, cfDNA, KRAS, ERCC1 and PD-L1 with clinical response to therapy (chemotherapy, IMMUNO or targeted therapy) in stage IV NSCLC pts. Method: Blood was drawn from 35 pts under various treatments (TX) every 6-8 weeks, at the same time that CT scans were done. CfRNA was extracted from the resulting plasma and reverse transcribed with random hexamers to cDNA. Levels of cfRNA, KRAS, ERCC1 and PDl-1 were quantitated by RT-qPCR and correlated with pts clinical response (CR/PR/SD/PD), as determined by CT scans. Results: 35 NSCLC pts were enrolled in a 2-year clinical study. 25 of 35 pts completed at least two cycles of TX and had CT scans done. 4/4 pts with partial response (PR) had no change (NC) or decrease (DEC) cfRNA; 6/8 pts with progressive disease (PD) showed INC levels of cfRNA, 9/13 pts with stable disease (SD) showed either no NC or DEC cfRNA, corresponding to 76%
concordance between cfRNA and clinical responses. PD-L1 expression measured in plasma cfRNA matched the tissue expression in 7/10 pts. In the one pt where PD-L1 was (-) in blood and (+) in tissue there was PD on IMMUNO. Among 8 pts treated with IMMUNO: 3/3 pts with PD showed INC PD-L1 cfRNA expression, 3/3 pts with SD had NC in negative PD-L1 status, and 2 pts with PR showed DEC PD-L1 cfRNA, corresponding to 100% correlation between PD-L1 expression levels and pt response. Ten pts harbored KRAS mutations in cfDNA.
Of those with KRAS+ status by tissue-based testing, 83% matched with cfDNA results. Among KRAS+ pts, 80% (8/10) showed PD-L1 cfRNA expression in same blood draws with KRAS+ cfDNA, suggesting correlation between these cfDNA and cfRNA analyses. ERCC1 and response to platinum doublets correlated in 8/10 pts (80%). Conclusion: There was concordance between tissue and blood-based testing in both DNA (KRAS mutations, 83%) and RNA (ERCC1 80% and PD-L1 expression, 70%). Significant association was observed between clinical response and changes in plasma cfRNA levels (76%). While on IMMUNO, plasma levels of PD-L1 expression could be used to monitor clinical responses. Keywords: liquid biopsies, immunotherapy, PD-L1, cfRNA
